EASL Clinical Practice Guidelines: Drug-induced liver injury.
No Thumbnail Available
Identifiers
Date
2019-03-27
Authors
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu
Clinical Practice Guideline Panel: Chair:
Panel members
EASL Governing Board representative:
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Description
MeSH Terms
Adult
Aged
Chemical and Drug Induced Liver Injury
Fatty Liver
Female
Histocompatibility Testing
Humans
Liver Neoplasms
Male
Middle Aged
Mitochondria
Practice Guidelines as Topic
Risk Factors
Aged
Chemical and Drug Induced Liver Injury
Fatty Liver
Female
Histocompatibility Testing
Humans
Liver Neoplasms
Male
Middle Aged
Mitochondria
Practice Guidelines as Topic
Risk Factors